Myeloablative conditioning regimens commonly lead to prolonged anorexia and poor oral intake. In a prospective study of 147 patients receiving CY, total body irradiation and allogeneic hematopoietic cells, we determined the extent of decline in oral intake and assessed plasma cytokine levels and development of acute GVHD as explanations for protracted anorexia. For each patient, daily oral caloric intake was expressed as a percent of estimated basal requirements, calculated as basal energy expenditure, through day 20. Oral caloric intake was significantly reduced in 92% of patients and remained low. The nadir in oral intake occurred at days 10-12, when median oral caloric intake was 3% of basal energy requirements. Plasma cytokines known to affect appetite (IL2, IL6, tumor necrosis factor-alpha) were significantly elevated above normal following conditioning therapy (Po0.001 for each cytokine). Acute GVHD did not appear to affect oral intake to transplant day 20 in this cohort of patients; however, plasma levels of IL6 rose steeply before the clinical onset of GVHD. Persistent fever occurred with the greatest frequency in patients with most profound reduction in oral intake. We conclude that prolonged alterations in oral intake following this myeloablative regimen may be related to circulating cytokines known to alter eating behavior.
Introduction
Although intense nausea and vomiting occur during the administration of myeloablative conditioning regimens, 1 most patients persist with gastrointestinal symptoms of nausea, anorexia and diarrhea for weeks after the completion of conditioning therapy. [2] [3] [4] As a result, patients are often in negative nitrogen balance and thus, require nutritional support (usually parenteral nutrition) to maintain lean body mass. 2, [5] [6] [7] [8] The reasons for persistence of gastrointestinal symptoms for weeks following myeloablative conditioning therapy and allografting are not entirely clear. High-dose conditioning regimens damage the oral and intestinal epithelium but the epithelial regenerative response is robust, with rapid re-epithelialization of intestinal mucosa after day 7. 9 Acute GVHD may also present with gastrointestinal symptoms, with a median day of onset of 14-19 days after transplant, depending on the source of donor hematopoietic cells. 4 In this study, we prospectively measured oral caloric intake and collected blood samples through transplant day 20 in a cohort of patients receiving the same conditioning regimen (CY/TBI), allogeneic stem cells and GVHD prophylaxis (calcineurin inhibitor and methotrexate). Our objectives were (1) to determine the extent of decline in oral intake and its duration following this regimen of conditioning therapy; (2) to assess plasma cytokine levels as a possible explanation for protracted anorexia and (3) to assess whether poor oral intake had adverse clinical consequences other than those related to caloric balance. We also examined the association between acute GVHD and oral intake during this time period, as the onset of GVHD often overlaps with the gastrointestinal toxicity from myeloablative conditioning regimens. 4 The overall aim of this work was to identify an underlying mechanism for prolonged inability to eat following a myeloablative conditioning regimen, one that could be treated. The results support the hypothesis that elevated levels of plasma cytokines known to affect appetite-IL2, IL6 and tumor necrosis factor-alpha (TNFa)-are the proximate cause of appetite suppression following a myeloablative regimen.
Patients and methods

Patients
Adults and children with hematologic malignancies who underwent an allogeneic transplant following a conditioning regimen of CY/TBI between April 1997 and January 2000 were studied. This cohort has been described previously with reference to CY metabolism and mortality; 10 the demographics of the cohort are shown in Table 1 . Data extraction and analysis for the current research were carried out under a protocol approved by the Fred Hutchinson Cancer Research Center Institutional Review Board.
Technique of hematopoietic cell transplant
Patients were conditioned with CY 120 mg/kg and TBI 9-14.4 Gy over a seven-day period as previously described. 10 Hematopoietic cell transplant (HCT) recipients received donor stem cells on 'day 0' and all subsequent events are timed from this date. Prophylaxis was given for emesis during conditioning therapy (ondansetron), GVHD (a calcineurin inhibitor plus methotrexate) and for infections with Herpes simplex virus (acyclovir), Pneumocystis jiroveci (trimethoprim/sulfamethoxazole) and Candida sp. (fluconazole). Cytomegalovirus antigen was monitored at weekly intervals; preemptive treatment with ganciclovir was initiated for positive blood tests.
11
Study design
This study prospectively generated data on caloric intake and called for blood samples to be drawn at set intervals, but the hypothesis that oral intake was related to plasma cytokine levels was examined in retrospect. The study followed all patients enrolled for 28 days, from the start of their conditioning regimen through day 20 post transplant. The following parameters were measured during this time: daily oral caloric intake, plasma cytokines (as described below) and clinical outcomes. Our Nutrition Section staff calculated on a daily basis each patient's nutrient intake by oral, enteral and parenteral routes from before the initiation of conditioning therapy through day 20 post transplant. We later entered this information into a database. For each patient, daily oral caloric intake was expressed as a percent of estimated basal requirements. Estimated basal requirements were calculated as basal energy expenditure (BEE) according to the Harris-Benedict formulas and Altman Dittmer formulas for adults and children weighing up to 75 kg, respectively: 12, 13 for women, BEE ¼ (655 þ (9.6 Â weight in kilos) þ (1.8 Â height in cm)À (4.7 Â age in years)); for men, BEE ¼ (66 þ (13.7 Â weight in kilos) þ (5 Â height in cm)À(6.8 Â age in years)). Thus, daily oral intake was the kilocalories ingested by the patient, divided by BEE and expressed as a percentage.
The clinical outcome measures that were tracked were the number of days during which a patient was febrile, the presence of positive blood cultures through day 20, the day of onset and ultimate severity (peak grade) of acute GVHD, and non-relapse mortality by transplant day 100. Body temperature was monitored every 4 h in hospitalized patients through day 20. Each day during which a patient had a maximum temperature greater than 38.01C was considered a day with fever. The total number of days with at least one febrile episode from the start of conditioning to day 20 was counted for each patient. Blood cultures were performed for fever evaluation and as surveillance for patients on high-dose corticosteroids (greater than 1 mg/ kg). A positive blood culture required additional daily cultures per clinical protocol until two consecutive negative cultures were obtained. Infections were classified as bacteremia or fungemia. Bacteremia was defined as the occurrence of one or more positive blood cultures with any organism regardless of associated symptoms. A bacteremia event was defined by the occurrence of a positive blood culture, even if it contained multiple organisms. Micrococcus or Corynebacterium species or aerobic diptheroids (other than group JK) were excluded as laboratory contaminants if considered so by consultation with infectious disease consultants and thus documented in the patient's medical records. Fungemia was defined as the occurrence of one or more positive blood cultures with any fungus regardless of associated symptoms. Aspergillus in the blood without other systemic evidence of Aspergillus infection was excluded as a laboratory contaminant if considered so by infectious disease consultants and thus documented in patient medical records. The number of blood stream infections was calculated by counting an infection with a specific organism only once, regardless of the number of subsequent positive cultures with the same organism during the first 20 days post transplant.
Plasma cytokine levels
Blood samples were taken at weekly intervals for determination of plasma cytokine levels (IL1a, IL1b, IL2, IL4, IL6, TNFa, soluble tumor necrosis factor receptor p55, IL1-receptor antagonist, IL10, IFNg, transforming growth factor (TGF)b1). Blood drawn from the patient's central venous catheter were placed in tubes containing potassium oxalate and sodium fluoride. After centrifugation at 41C, Table 1 Demographic characteristics of patients receiving CY 120 mg/kg and TBI as myeloablative therapy followed by allogeneic transplantation (N ¼ 147) 10 Characteristic Results plasma was immediately removed and aliquots were frozen at minus 801C until analysis. Cytokine assays were run on 96-well clear plastic microplates coated with a capture antibody diluted in sodium carbonate buffer, as previously described. 14 A standard curve was created for each plate by the serial dilution of the standards, and the sample cytokine quantified from the standard curve. Operating characteristics and normal ranges for each assay were determined by analysis of blood from 39 volunteers.
Diagnosis and severity of acute GVHD GVHD was scored as present or absent through transplant day 100. The date of onset of GVHD was defined according to the onset of skin rash characteristic of GVHD or the date of gastroenterology consultation leading to a diagnosis of GVHD, whichever came first. Patterns for grading followed the original Seattle criteria with adjustments for complications other than GVHD made according to the convention endorsed by a consensus conference in 1994. 15 Briefly summarized, grade 0 indicates the absence of clinical manifestations of GVHD. Grade 1 GVHD indicates stage 1 or 2 skin involvement (o50% of body surface involved). Grade 2 GVHD indicates stage 3 skin involvement (450% rash) or adjusted stage 1 liver (total serum bilirubin 2-3 mg/ dl) or gut (upper gastrointestinal symptoms or diarrhea with stool volume o1000 ml/day) involvement. Grade 3 GVHD indicates stage 4 skin involvement (bullae) or adjusted stage 2-4 liver (bilirubin 43.0 mg/dl) or gut (stool volume 41000 ml/day) involvement, without GVHD as a major contributory cause of death. Grade 4 GVHD indicates that GVHD was a major contributory cause of death.
Statistical methods
Summary statistics such as median and range were calculated for continuous or count data. For categorical variables, frequencies were calculated. To test for association between groups defined by oral intake, Fisher's exact test of independence was used to detect differences in the frequency data. The non-parametric Wilcoxon rank sum test or one-sample t-test was used to compare continuous (or count) data, as appropriate. We compared baseline caloric intake for each individual in the cohort to 3-day averages of caloric intake for that individual for the first 20 days post transplant, using the Wilcoxon matched pairs signed rank test (to account for pairing of data within subjects). All P-values are two-sided.
Approach to statistical analyses Baseline oral caloric intake for each individual in the cohort was defined as their average oral intake during the interval (day minus 8 through minus 6). The hypothesis that decreased oral caloric intake was related to levels of plasma cytokines was tested by comparing peak plasma cytokine values (as the median values) during days 0-10 to median levels from normal human volunteers. After documenting the sustained decrease in oral intake that results from myeloablative therapy and HCT, the association between poor luminal nutrition during the immediate post transplant period and selected outcome measures was examined in the cohort. The frequency of febrile days during days 6 through 20 (o8 vs X8 days of fever) were examined in relation to the level of oral intake in the previous period (days [1] [2] [3] [4] [5] , as was the frequency of positive blood culture and day 100 non-relapse mortality. For each of these analyses, oral intake was categorized as p30% vs 430% of BEE.
The occurrence of acute GVHD by severity (grades 0-4) was determined and the inter-relationships between acute GVHD and oral intake through day 20 was examined. Within groups of patients with grade 0 or 1 and grades 2-4 GVHD, we compared baseline caloric intake for each individual in the cohort to 3-day averages of caloric intake for that individual for the first 20 days post transplant, using the Wilcoxon matched pairs signed rank test. To test the hypothesis that development of acute GVHD was associated with oral intake, we compared oral intake at each 3-day time interval between patients with grades 0-1 GVHD and those with grades 2-4 GVHD using the Wilcoxon rank sum test.
For a subgroup of 107 patients who had serial blood samples available for cytokine analysis, cytokine levels were analyzed during the period from 15 days before the onset of GVHD up to the day of onset of GVHD for the 96 patients who developed GVHD. For the subgroup of 11 patients never diagnosed with GVHD, cytokine levels were analyzed from transplant to the day of onset was arbitrarily assigned as day 15 after transplant, which corresponds to the median day of onset for patients with GVHD. Cytokine levels were log-transformed and slopes computed for each patient based on all available measurements in the 15-day window. A one-sample t-test was then used to test whether the mean slope was 0. To aid interpretation, the mean slopes on the log scale have been re-expressed as percent change in cytokine level per week. For the analysis in Table 3 , median values were computed based on the last available cytokine level for each individual within the 15-day window. Comparisons between groups for each cytokine were performed using the Wilcoxon two-sample test.
Results
Decline in oral intake during and after CY/TBI The median oral intake for the cohort during days minus 8 through minus 6 was 56% (range 0-270%) of basal requirements. A statistically significant decline in oral caloric intake occurred immediately after the first dose of CY, reaching a nadir (median intake 3%, range 0-210% of BEE) during days 10-12 post transplant (Figure 1 ). Oral mucositis developed in all patients, scored prospectively as mild to moderate. Oral caloric intake began to increase thereafter, leveling off through the end of the observation period (transplant day 20). At day 20, the median oral intake was 25% of basal requirements (range 0-225%).
Alterations in plasma cytokine levels following CY/TBI Peak plasma cytokine levels during days À1 through À10 were significantly (Po0.01) higher than normal values for all cytokines measured except for IL1a and IL4 and significantly lower than normal for TGFb1 (o0.0001) ( Table 2 ). Levels of plasma cytokines known to affect appetite were significantly elevated over normal in almost all patients in the study cohort, particularly for IL2 (430-fold higher than normal), IL6 (424-fold higher) and TNFa (47-fold higher). As there were so few patients with normal oral caloric intake during the study period, we could not detect associations between cytokine levels and percent of basal requirements ingested for any of the measured cytokines (data not shown).
Association between acute GVHD and oral intake to day 20 Acute GVHD developed in 130/147 patients (91%), of whom four had peak GVHD activity scored as grade 1, 94 as grade 2, 27 as grade 3 and nine as grade 4 (that is, grades 2-4 GVHD developed in 88% of patients). Thirteen patients had no clinical evidence of acute GVHD. The median day of onset of GVHD grades 2-4 was day 14.5. As shown in Figure 2 , there is little apparent difference in oral intake to day 20 among patients with peak grades 0-1 vs grades 2-4 GVHD. Comparison of oral intake at specified 3-day time intervals in these two cohorts showed no statistical differences at any interval to day 20 (data not shown). Table 2 Peak plasma cytokine levels during days À1 through À10 post transplant, compared to normal plasma cytokine levels Association between acute GVHD and plasma cytokine levels For the analysis of a subgroup of 107 patients who had serial cytokine values available, acute GVHD developed in 96/107 patients (90%), of whom five had grade 1, 61 grade 2, 22 grade 3 and eight grade 4 (that is, grade 3/4 GVHD developed in 28% of patients). Eleven patients had no clinical evidence of acute GVHD. Plasma levels of four cytokines were significantly changed during the 15-day interval before the clinical onset of acute GVHD that was ultimately scored as grades 3-4: IL1a ( þ 68.2%); IL6 ( þ 361.1%); sTNF receptor ( þ 20.2%) and TGFb1 (À43.4%) (all values are expressed as percent change per week; see Table 3 ). There were no changes in plasma levels of IL1b, IL2, IL4, IL10, TNFa, IFNg or IL1 receptor antagonist during this interval (data not shown). In patients who developed grade 2 GVHD, plasma levels of IL6, sTNF receptor and TGFb1 were significantly changed during this 15-day interval (Table 3) . Changes in IL6 and TGFb1 were notable in that the magnitude of change was proportional to the severity of GVHD (Table 2 ). There were no changes for any cytokine measured among patients with grade 1 GVHD or no GVHD in the comparable time period (Table 2 ). Figure 3 displays the slopes of changing plasma IL6 levels for individual patients, along with the average slope, during the 15-day time intervals before the onset of acute GVHD, by the ultimate severity of GVHD.
Other clinical events to transplant day 20
During the period days 0-20 post transplant, there were 162 days of fever (range 0-11 days) for those patients eating more than 30% of BEE (N ¼ 43) and 462 days of fever (range 0-17 days) for those eating less than 30% of BEE (N ¼ 103). For patients eating p30% caloric needs during days 1-5, there was a statistically significant difference in the frequency of persistent fever (8 or more febrile days during days 6-20), compared to patients eating 430% caloric needs (20/103 (19.4%) vs 1/43 (2.3%), P ¼ 0.01 Fisher's Exact Test). The frequency of positive blood cultures during the period of interest, days 6-20, was relatively low (26 positive blood cultures over a 15-day time period, among 146 patients). There were no statistically significant associations observed between the percent of BEE ingested (less than vs greater than 30% of caloric needs) during days 1-5 and number of subsequent positive blood cultures (P ¼ 0.817). Twenty-one of the study participants died as a result of non-relapse events by 100 days post HCT. We observed an inverse numerical association between the percent of BEE ingested orally and non-relapse mortality (NRM) (through day 100) (that is, patients ingesting o30% of their caloric requirements had numerically greater mortality), although this was not a statistically significant association (data not shown).
Discussion
Data from this study show that myeloablative conditioning therapy with CY/TBI was followed by profound decreases in oral caloric intake for at least 20 days after completion of therapy. Following the completion of conditioning therapy and before the clinical onset of acute GVHD, levels of plasma cytokines known to affect appetite were signifi- Table 3 Changes of plasma cytokine levels per week during the 15-day period before the clinical onset of acute GVHD (n ¼ 107)
Peak GVHD grade IL1a IL6 sTNF receptor TGFb1 cantly elevated over normal in almost all patients in the study cohort, particularly for IL2 (430-fold higher than normal), IL6 (424-fold higher) and TNFa (47-fold higher). Patients with the most profound decreases in oral caloric intake had the greatest frequency of persistent fever, through day 20 post transplant. In patients who then developed GVHD, the plasma levels of IL6 increased steeply, in contrast to IL6 levels in patients without GVHD. High-dose chemotherapy and TBI are known to cause nausea and vomiting during their administration. While ondansetron is effective in reducing the immediate toxicity of conditioning therapy, there was no apparent effect on decreased oral caloric intake in the weeks following therapy. Oral intake was so severely affected that the majority of patients did not return to baseline even 3 weeks after transplant. For example, the median caloric intake at the end of the 28-day study period was 25% of basal caloric needs, the same as the median intake seen immediately after CY/TBI. The nadir of oral caloric intake did not occur during myeloablative therapy, but at days 10-12 post transplant. During this interval, only half of the patients were eating more than 3% of their caloric needs. We hypothesize that inability to eat and the resultant decreased oral caloric intake after transplant are initially a function of the toxicity of this regimen to oropharyngeal and intestinal epithelium, 10 but the mechanisms by which CY/TBI conditioning causes such protracted anorexia are not known. As all patients received essentially the same conditioning regimen, it seems likely that the degree of mucosal damage was similar throughout this cohort. However, initial damage to the intestinal epithelium may be exacerbated by the absence of luminal nutrition, as both small intestinal and colonic epithelial cells rely on luminal nutrients for growth factor stimulation and for metabolic fuel (polyamines for small intestinal epithelium and short chain fatty acids for colonic epithelium). 16, 17 In other words, lack of luminal nutrients may delay the process of epithelial regeneration. A recent study also suggests that poor oral intake early after HCT is associated with an increased risk of developing severe GVHD. 18 The mechanisms by which CY/TBI conditioning leads to protracted nausea and anorexia probably involves both neural and humoral pathways emanating from the gastrointestinal tract. We did not examine the neural pathways. Cytokine levels were analyzed as the peak value between days 1 and 10, reflecting the activity of primarily innate immune mechanisms, as host cellular immunity had been ablated and substantive engraftment with donor cells had not yet occurred. We hypothesize that the profound depression of eating behavior seen throughout the study period was related to the effect of circulating cytokines on brain appetite centers. [19] [20] [21] [22] With the exception of IL1a and TGFb1, all cytokines measured during days 1-10 were significantly higher than normal ( Table 2 ). The most striking increases were in IL2, IL 6 and TNFa. These same pro-inflammatory cytokines have been implicated in the development of anorexia and cachexia in human 23, 24 and animal models. [25] [26] [27] In humans, there is also a direct correlation between increased gut permeability and plasma IL6 elevation. 28 Normal volunteers who received intravenous endotoxin after bowel rest demonstrated increased gut permeability with bacterial translocation and pro-inflammatory cytokine release compared to volunteers receiving enteral nutrition. 29 We speculate that the dominant biologic processes operative during days 1-10 post transplant are gut mucosal damage, translocation of bacteria and endotoxin, and stimulation of innate immunity. 10, 30 The gut mucosa is a site of acute phase protein and pro-inflammatory cytokine production in response to inflammation, sepsis, severe injury and other critical and chronic illnesses. [31] [32] [33] However, in the weeks before engraftment, we cannot be sure that donor alloimmune cells are not amplifying the inflammatory response despite their relatively small numbers.
The effects of the conditioning regimen on oral intake are clearly intertwined with the development of acute GVHD, where the most common gastrointestinal symptoms are those of anorexia, nausea and vomiting. 34 However, the degree of suppression of oral intake across time in this study is remarkably similar among cohorts of patients with no GVHD and grades 2-4 GVHD. The cytokine profile of patients with GVHD suggests that IL6 levels increase markedly in the days leading up to the clinical onset of GVHD. The slope of rise of IL6 was also related to the severity of subsequent acute GVHD, that is, patients with more severe acute GVHD had IL6 changes in plasma that were greater than those from patients with less severe GVHD. Other investigators have also described a relation between circulating IL6 levels and GVHD. [35] [36] [37] These data, combined with less substantial changes in other cytokines in the 15-day period before the onset of GVHD, suggest that IL6 is the dominant circulating cytokine associated with the onset of GVHD. If the concept of 'cytokine storm' (that is, an acute process involving multiple organs caused by local release of cytokines and circulating inflammatory mediators) is correct, then IL6 appears to be the most important circulating cytokine in patients with acute GVHD. The strikingly low levels of TGFb1 before the onset of GVHD are consistent with the hypothesis that the absence of an inhibitor of T-cell activation and proliferation leads to uninhibited proliferation of inflammatory cells. [38] [39] [40] [41] TGFb1 also normally inhibits class II MHC expression, such that the absence of TGFb1 might promote recipient antigen presentation to donor T cells. 42 Because almost all patients in the study cohort were ingesting inadequate calories (only 11/147 (7%) were eating470% of requirements during days 1-5), we were unable to examine a critical question: do patients who are able to maintain oral intake have a lower plasma cytokine profile? That is, are gut damage and depression of appetite prolonged by the absence of luminal nutrients, and as a corollary, would provision of luminal nutrients lead to preservation of the mucosal barrier and accelerated gut mucosal recovery? In other patient populations who are critically ill or severely injured, luminal nutrition decreases septic morbidity (pneumonias, intra-abdominal abscesses and line infections). 43, 44 The complementary data for HCT recipients does not exist, as the standard of care in this population remains parenteral nutrition. Several small series, however, have demonstrated that luminal nutrition is feasible and well tolerated, including tube feeding. The fact that patients with the lowest oral intake had more fever in the first 20 days post transplant raises the possibility that providing more oral nutrients would confer clinical benefit and possibly improved survival.
We propose that clinical trials be undertaken to test the hypothesis that the plasma cytokines IL2 and IL6 are the proximate cause of protracted anorexia and poor oral intake following myeloablative conditioning regimens. The expected clinical benefits of better oral intake would be earlier discontinuation of TPN, the prospect of faster gut mucosal recovery and preservation of the gut mucosal barrier to bacteria and endotoxin. There is precedent for using anti-cytokine strategies to improve systemic symptoms. For example, in patients with Castleman's disease, a lymphoproliferative disorder, treatment with either an anti-IL6 antibody or a receptor antibody effects resolution of fever, fatigue and malaise. 45, 46 Several biological agents that inhibit IL6 activity are being tested in patients with inflammatory bowel disease, 47 rheumatoid arthritis, [48] [49] [50] Blymphoproliferative disease 51 and renal cell carcinoma. 52 Biological therapies that interfere with the effects of IL6 could also be used to test the hypothesis that circulating IL6 contributes to signs and symptoms of GVHD. 53, 54 
